Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data. Luspatercept-aamt (Reblozyl) improved the rate and ...
A new analysis from the COMMANDS trial of erythroid maturation agent luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) shows not only sustained, longer-term benefits over ...
Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa. Luspatercept-aamt (Reblozyl) ...
Weight loss injections have emerged as a notable alternative to traditional methods of losing weight. These types of injections are designed to support weight management by affecting the biological ...
Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the originator's ...
An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS. Reblozyl (luspatercept) has become the new standard ...
Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the ...
(RTTNews) - Zai Lab Limited (ZLAB) and argenx (ARGX) announced that China's National Medical Products Administration or NMPA approved the Biologics License Application or BLA for efgartigimod alfa ...
Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl. Patients with myelodysplastic syndrome (MDS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results